Innovating Works

YUMAB

A stranger
GLIOTRAIN: Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational... YUMAB GmbH participó en un H2020: H2020-MSCA-ITN-2017 Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patien...
2017-08-29 - 2021-08-31 | financed
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.